Phase 1 Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From the Melanoma-Associated Antigens MART-1 and gp100

Journal of Immunotherapy

Volumn 23, Issue 4, 2000, Pages 487-498

  Panelli, Monica C ^a   Wunderlich, John ^a   Jeffries, Justin ^a   Wang, Ena ^a   Mixon, Arnold ^a   Rosenberg, Steven A ^a   Marincola, Francesco M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti tumor response; Intravenous administration; Melanoma antigen vaccination; Patient monitoring

Indexed keywords

MELANOMA ANTIGEN; MELANOMA VACCINE;

ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DENDRITIC CELL; DRUG INDICATION; FEMALE; FEVER; HUMAN; MALE; MELANOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIGEN PRESENTATION; ANTIGENS, DIFFERENTIATION; CANCER VACCINES; CELL LINE; CELLS, CULTURED; DENDRITIC CELLS; EPITOPES; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRAVENOUS; INTERLEUKIN-2; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033934224     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200007000-00013     Document Type: Article

References (39)

1. Restifo NP, Wunderlich JR. Principles of tumor immunity: biology of cellular immune responses. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia: JB Lippincott, 1996, 3-21.
2. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18:175-82.
3. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997; 18:267-8.
4. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-52.
5. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas [see comments]. J Exp Med 1994; 180:35-42.
6. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154:3961-8.
7. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91:3515-3519.
8. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91:6458-62.
9. Bettinotti M, Kim CJ, Lee K-H, et al. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J Immunol 1998; 161:877-89.
10. Kim CJ, Parkinson DR, Marincola FM. Immunodominance across the HLA polymorphism: implications for cancer immunotherapy. J Immunother 1997; 21:1-16.
11. Salgaller ML, Afshar A, Marincola FM, et al. Recognition of multiple epitopes in the human melanoma antigen gp 100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995; 55:4972-9.
12. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995; 154:2257-65.
13. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 binding residues. J Immunol 1996; 157:2539-48.
14. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A [see comments]. Cancer J Sci Am 1997; 3:37-44.
15. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56:4749-57.
16. Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995; 95:341-9.
17. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9:271-96.
18. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity [comment]. J Exp Med 1996; 183:7-11.
19. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1:1297-1302.
20. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo [see comments]. J Exp Med 1996; 183:317-22.
21. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo Jr. LD Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity [see comments]. J Exp Med 1996; 183:283-87.
22. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines [see comments]. J Exp Med 1996; 183:87-97.
23. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109-18.
24. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83-93.
25. Kim CJ, Prevette T, Cormier JN, et al. Dendritic cells infected with poxviruses encoding MART-1/MelanA sensitize T lymphocytes in vitro. J Immunother 1997; 20:276-86.
26. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52-8.
27. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-32.
28. Player MA, Barracchini KC, Simonis TB, et al. Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols. J Immunother 1996; 19:357-63.
29. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides [see comments]. Nature 1992; 356:443-6.
30. Brodsky FM, Parham P. Monomorphic anti-HLA-A, B, C monoclonal antibodies detecting molecular subunits and combinatorial determinants. J Immunol 1982; 128:129-35.
31. Tsujisaki M, Sakaguchi K, Igarashi M, et al. Fine specificity and idiotype diversity of the murine anti-HLA-A2, A28 monoclonal antibodies CR11-351 and KS1. Transplantation 1988; 45:632-9.
32. Cella M, Dohring C, Samaridis J, et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 1997; 185:1743-51.
33. Cormier JN, Panelli MC, Hackett JA, et al. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer 1999; 80:781-90.
34. Rosenberg SA, Yang JC, Schwartzentruber D, et al. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-7.
35. Pockaj BA, Sherry RM, Wei JP, et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994; 73:1731-7.
36. Kim CJ, Cormier JN, Roden M, et al. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. Ann Surg Oncol 1998; 5:64-76.
37. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4-T-helper and a T-killer cell [see comments]. Nature 1998; 393:474-8.
38. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184:747-52.
39. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9:10-16.